Profil
Jessica Jensen is currently the Executive Vice President-Clinical Development at POINT Biopharma, Inc. in the United States.
Prior to this, she was the Senior Vice President-Clinical Development at Progenics Pharmaceuticals, Inc. from 2018 to 2020.
She will also be the Executive Vice President-Clinical Development at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Jensen has a graduate degree from George Washington University and an undergraduate degree from St. Joseph's University.
Aktive Positionen von Jessica Jensen
| Unternehmen | Position | Beginn |
|---|---|---|
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2020 |
Ehemalige bekannte Positionen von Jessica Jensen
| Unternehmen | Position | Ende |
|---|---|---|
| POIT BIOP | Technik-/Wissenschafts-/F&E-Leiter | 27.12.2023 |
| PROGENICS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2020 |
Ausbildung von Jessica Jensen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicines for prostate cancer | Health Technology |
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
POINT Biopharma Global, Inc.
POINT Biopharma Global, Inc. BiotechnologyHealth Technology Develops radioligand therapies for the treatment of cancer | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Develops next-generation radioligand therapies for the treatment of cancer | Commercial Services |
















